1,012 Shares in Becton, Dickinson and Company (NYSE:BDX) Acquired by Burke & Herbert Bank & Trust Co.

Burke & Herbert Bank & Trust Co. purchased a new position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,012 shares of the medical instruments supplier’s stock, valued at approximately $237,000.

Other institutional investors also recently bought and sold shares of the company. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth approximately $27,000. OLD Point Trust & Financial Services N A purchased a new stake in Becton, Dickinson and Company during the 4th quarter valued at $29,000. DiNuzzo Private Wealth Inc. bought a new stake in shares of Becton, Dickinson and Company in the 4th quarter worth $30,000. Scarborough Advisors LLC purchased a new position in shares of Becton, Dickinson and Company in the fourth quarter worth $32,000. Finally, Accordant Advisory Group Inc purchased a new stake in shares of Becton, Dickinson and Company during the first quarter valued at $35,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BDX. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI cut their target price on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Barclays upped their price objective on Becton, Dickinson and Company from $305.00 to $312.00 and gave the company an “overweight” rating in a research report on Monday, May 6th. Raymond James lowered their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, Stifel Nicolaus raised their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Becton, Dickinson and Company has a consensus rating of “Moderate Buy” and an average target price of $279.50.

Insider Activity

In related news, SVP Thomas J. Spoerel sold 300 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $239.31, for a total transaction of $71,793.00. Following the completion of the sale, the senior vice president now owns 1,976 shares in the company, valued at $472,876.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.9 %

Shares of NYSE:BDX opened at $236.28 on Wednesday. The stock has a 50 day moving average of $233.46 and a 200 day moving average of $236.24. The company has a market cap of $68.29 billion, a PE ratio of 52.04, a price-to-earnings-growth ratio of 2.06 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $283.78. The company has a current ratio of 1.85, a quick ratio of 0.97 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The company’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.96 earnings per share. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.06 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.95 per share. The ex-dividend date is Monday, September 9th. This represents a $3.80 dividend on an annualized basis and a yield of 1.61%. Becton, Dickinson and Company’s dividend payout ratio is presently 83.70%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.